Enanta Pharmaceuticals (ENTA) Long-Term Deferred Tax (2014 - 2021)

Enanta Pharmaceuticals (ENTA) has 8 years of Long-Term Deferred Tax data on file, last reported at $345000.0 in Q2 2021.

• Quarterly Long-Term Deferred Tax fell 97.74% year-over-year to $345000.0 in Q2 2021, while the trailing twelve-month figure through Jun 2021 was $345000.0 (down 97.74% YoY) and the FY2020 annual result came in at $345000.0, down 96.96% from the prior year.
• Long-Term Deferred Tax steadied at $345000.0 in Q2 2021, from $345000.0 in the prior quarter.
• In the past five years, Long-Term Deferred Tax ranged from a high of $17.7 million in Q2 2017 to a low of $345000.0 in Q3 2020.
• A 5-year average of $8.5 million and a median of $9.2 million in 2018 frame the typical range for Long-Term Deferred Tax.
• Annual changes were most pronounced in 2017 — Long-Term Deferred Tax jumped 203.32% — and 2021, when it sank 97.74%.
• Tracing ENTA's Long-Term Deferred Tax over 5 years: stood at $7.6 million in 2017, then climbed by 22.2% to $9.2 million in 2018, then gained by 15.22% to $10.7 million in 2019, then sank by 96.76% to $345000.0 in 2020, then changed by 0.0% to $345000.0 in 2021.
• The last three Long-Term Deferred Tax figures came in at $345000.0 (Q2 2021), $345000.0 (Q1 2021), and $345000.0 (Q4 2020), per Business Quant data.